| P2Y13 receptor deficiency favors adipose tissue lipolysis and worsens insulin resistance and fatty liver disease. | P2Y13 receptor deficiency favors adipose tissue lipolysis and worsens insulin resistance and fatty liver disease.
Duparc T, Gore E, Combes G, Beuzelin D, Pires Da Silva J, Bouguetoch V, Marquès MA, Velazquez A, Viguerie N, Tavernier G, Arner P, Rydén M, Langin D, Sioufi N, Nasser M, Cabou C, Najib S, Martinez LO., Free PMC Article | 05/10/2024 |
| Erythrocytes from patients with ST-elevation myocardial infarction induce cardioprotection through the purinergic P2Y13 receptor and nitric oxide signaling. | Erythrocytes from patients with ST-elevation myocardial infarction induce cardioprotection through the purinergic P2Y(13) receptor and nitric oxide signaling.
Jiao T, Collado A, Mahdi A, Jurga J, Tengbom J, Saleh N, Verouhis D, Böhm F, Zhou Z, Yang J, Pernow J., Free PMC Article | 10/15/2022 |
| P2RY13 Exacerbates Intestinal Inflammation by Damaging the Intestinal Mucosal Barrier via Activating IL-6/STAT3 Pathway. | P2RY13 Exacerbates Intestinal Inflammation by Damaging the Intestinal Mucosal Barrier via Activating IL-6/STAT3 Pathway.
Wu X, Wei S, Chen M, Li J, Wei Y, Zhang J, Dong W., Free PMC Article | 08/27/2022 |
| Targeting the P2Y13 Receptor Suppresses IL-33 and HMGB1 Release and Ameliorates Experimental Asthma. | Targeting the P2Y(13) Receptor Suppresses IL-33 and HMGB1 Release and Ameliorates Experimental Asthma.
Werder RB, Ullah MA, Rahman MM, Simpson J, Lynch JP, Collinson N, Rittchen S, Rashid RB, Sikder MAA, Handoko HY, Curren BF, Sebina I, Hartel G, Bissell A, Ngo S, Yarlagadda T, Hasnain SZ, Lu W, Sohal SS, Martin M, Bowler S, Burr LD, Martinez LO, Robaye B, Spann K, Ferreira MAR, Phipps S. | 02/12/2022 |
| Evaluation of tumor microenvironmental immune regulation and prognostic in lung adenocarcinoma from the perspective of purinergic receptor P2Y13. | Evaluation of tumor microenvironmental immune regulation and prognostic in lung adenocarcinoma from the perspective of purinergic receptor P2Y13.
Wang J, Shi W, Miao Y, Gan J, Guan Q, Ran J., Free PMC Article | 01/15/2022 |
| P2Y13 and P2X7 receptors modulate mechanically induced adenosine triphosphate release from mast cells. | P2Y(13) and P2X(7) receptors modulate mechanically induced adenosine triphosphate release from mast cells.
Shen D, Shen X, Schwarz W, Grygorczyk R, Wang L. | 10/2/2021 |
| Nucleotides-Induced Changes in the Mechanical Properties of Living Endothelial Cells and Astrocytes, Analyzed by Atomic Force Microscopy. | Nucleotides-Induced Changes in the Mechanical Properties of Living Endothelial Cells and Astrocytes, Analyzed by Atomic Force Microscopy.
Gil-Redondo JC, Iturri J, Ortega F, Pérez-Sen R, Weber A, Miras-Portugal MT, Toca-Herrera JL, Delicado EG., Free PMC Article | 04/13/2021 |
| Common p2y13 polymorphisms are associated with plasma inhibitory factor 1 and lipoprotein(a) concentrations, heart rate and body fat mass and may modulate cardiovascular risk. | Common p2y(13) polymorphisms are associated with plasma inhibitory factor 1 and lipoprotein(a) concentrations, heart rate and body fat mass: The GENES study.
Verdier C, Ruidavets JB, Genoux A, Combes G, Bongard V, Taraszkiewicz D, Galinier M, Elbaz M, Ferrières J, Martinez LO, Perret B. | 04/27/2019 |
| The pattern of responsiveness to more selective P2-antagonists implies that both P2Y13 and P2X7 receptors are involved in Epsilon-toxin-of Clostridium perfringens induced hemolysis in human species. | Research articleHemolysis in human erythrocytes by Clostridium perfringens epsilon toxin requires activation of P2 receptors.
Gao J, Xin W, Huang J, Ji B, Gao S, Chen L, Kang L, Yang H, Shen X, Zhao B, Wang J., Free PMC Article | 04/20/2019 |
| results demonstrate a crosstalk between two metabotropic and one ionotropic purinergic receptor that regulates cAMP levels through adenylate cyclase 5 and modulates axonal elongation triggered by neurotropic factors and the PI3K-Akt-GSK3 pathway | Adenylate cyclase 5 coordinates the action of ADP, P2Y1, P2Y13 and ATP-gated P2X7 receptors on axonal elongation.
del Puerto A, Díaz-Hernández JI, Tapia M, Gomez-Villafuertes R, Benitez MJ, Zhang J, Miras-Portugal MT, Wandosell F, Díaz-Hernández M, Garrido JJ. | 06/8/2013 |
| Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) | Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
Bailey SD, Xie C, Do R, Montpetit A, Diaz R, Mohan V, Keavney B, Yusuf S, Gerstein HC, Engert JC, Anand S, DREAM investigators., Free PMC Article | 09/15/2010 |
| Observational study of gene-disease association. (HuGE Navigator) | Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.
Talmud PJ, Drenos F, Shah S, Shah T, Palmen J, Verzilli C, Gaunt TR, Pallas J, Lovering R, Li K, Casas JP, Sofat R, Kumari M, Rodriguez S, Johnson T, Newhouse SJ, Dominiczak A, Samani NJ, Caulfield M, Sever P, Stanton A, Shields DC, Padmanabhan S, Melander O, Hastie C, Delles C, Ebrahim S, Marmot MG, Smith GD, Lawlor DA, Munroe PB, Day IN, Kivimaki M, Whittaker J, Humphries SE, Hingorani AD, ASCOT investigators, NORDIL investigators, BRIGHT Consortium., Free PMC Article | 09/15/2010 |
| (p2y13 purinoceptor) | P2Y(13): identification and characterization of a novel Galphai-coupled ADP receptor from human and mouse.
Zhang FL, Luo L, Gustafson E, Palmer K, Qiao X, Fan X, Yang S, Laz TM, Bayne M, Monsma F Jr. | 01/21/2010 |